Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical experience with 100 small intestine GIST patients and i...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-10-01
|
Series: | BMC Gastroenterology |
Online Access: | http://www.biomedcentral.com/1471-230X/6/29 |
id |
doaj-042833e649e9408abf7efc6935de0991 |
---|---|
record_format |
Article |
spelling |
doaj-042833e649e9408abf7efc6935de09912020-11-25T03:39:56ZengBMCBMC Gastroenterology1471-230X2006-10-01612910.1186/1471-230X-6-29Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylateJan Yi-YinHwang Tsann-LongChao Tzu-ChiehWu Pei-YuYeh Chun-NanLee Li-YuWu Ting-JungChen Miin-Fu<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical experience with 100 small intestine GIST patients and identify predictors for long-term disease-free survival (DFS) and overall survival (OS) to clarify the difference between high- and low-risk patients.</p> <p>Methods</p> <p>The clinicopathologic and follow-up records of 100 small intestine GIST patients who were treated at Chung Gung Memorial Hospital between 1983 and 2002 were retrospectively reviewed. Clinical and pathological factors were assessed for long-term DFS and OS by using a univariate log-rank test and a multivariate Cox proportional hazard model.</p> <p>Results</p> <p>The patients included 52 men and 48 women. Their ages ranged from 27 to 82 years. Among the 85 patients who underwent curative resection, 44 (51.8%) developed disease recurrence (liver metastasis was the most common form of recurrence). The follow-up period ranged from 5 to 202 months (median: 33.2 months). The 1-, 3-, and 5-year DFS and OS rates were 85.2%, 53.8%, and 43.7%, and 91.5%, 66.6%, and 50.5%, respectively. Using multivariate analysis, it was found that high tumor cellularity, mitotic count >5/50 high-power field, and a Ki-67 index ≧10% were three independent factors that were inversely associated with DFS. However, absence of tumor perforation, mitotic count < 5/50 high power field, and tumor with low cellularity were predictors of long-term favorable OS.</p> <p>Conclusion</p> <p>Tumors with low cellularity, low mitotic count, and low Ki-67 index, which indicate low risk, predict a more favorable DFS for small intestine GIST patients undergoing curative resection. Absence of tumor perforation with low mitotic count and low cellularity, which indicates low risk, can predict long-term OS for small intestine GIST patients who have undergone curative resection.</p> http://www.biomedcentral.com/1471-230X/6/29 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jan Yi-Yin Hwang Tsann-Long Chao Tzu-Chieh Wu Pei-Yu Yeh Chun-Nan Lee Li-Yu Wu Ting-Jung Chen Miin-Fu |
spellingShingle |
Jan Yi-Yin Hwang Tsann-Long Chao Tzu-Chieh Wu Pei-Yu Yeh Chun-Nan Lee Li-Yu Wu Ting-Jung Chen Miin-Fu Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate BMC Gastroenterology |
author_facet |
Jan Yi-Yin Hwang Tsann-Long Chao Tzu-Chieh Wu Pei-Yu Yeh Chun-Nan Lee Li-Yu Wu Ting-Jung Chen Miin-Fu |
author_sort |
Jan Yi-Yin |
title |
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate |
title_short |
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate |
title_full |
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate |
title_fullStr |
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate |
title_full_unstemmed |
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate |
title_sort |
surgical treatment and prognostic analysis for gastrointestinal stromal tumors (gists) of the small intestine: before the era of imatinib mesylate |
publisher |
BMC |
series |
BMC Gastroenterology |
issn |
1471-230X |
publishDate |
2006-10-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical experience with 100 small intestine GIST patients and identify predictors for long-term disease-free survival (DFS) and overall survival (OS) to clarify the difference between high- and low-risk patients.</p> <p>Methods</p> <p>The clinicopathologic and follow-up records of 100 small intestine GIST patients who were treated at Chung Gung Memorial Hospital between 1983 and 2002 were retrospectively reviewed. Clinical and pathological factors were assessed for long-term DFS and OS by using a univariate log-rank test and a multivariate Cox proportional hazard model.</p> <p>Results</p> <p>The patients included 52 men and 48 women. Their ages ranged from 27 to 82 years. Among the 85 patients who underwent curative resection, 44 (51.8%) developed disease recurrence (liver metastasis was the most common form of recurrence). The follow-up period ranged from 5 to 202 months (median: 33.2 months). The 1-, 3-, and 5-year DFS and OS rates were 85.2%, 53.8%, and 43.7%, and 91.5%, 66.6%, and 50.5%, respectively. Using multivariate analysis, it was found that high tumor cellularity, mitotic count >5/50 high-power field, and a Ki-67 index ≧10% were three independent factors that were inversely associated with DFS. However, absence of tumor perforation, mitotic count < 5/50 high power field, and tumor with low cellularity were predictors of long-term favorable OS.</p> <p>Conclusion</p> <p>Tumors with low cellularity, low mitotic count, and low Ki-67 index, which indicate low risk, predict a more favorable DFS for small intestine GIST patients undergoing curative resection. Absence of tumor perforation with low mitotic count and low cellularity, which indicates low risk, can predict long-term OS for small intestine GIST patients who have undergone curative resection.</p> |
url |
http://www.biomedcentral.com/1471-230X/6/29 |
work_keys_str_mv |
AT janyiyin surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate AT hwangtsannlong surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate AT chaotzuchieh surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate AT wupeiyu surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate AT yehchunnan surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate AT leeliyu surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate AT wutingjung surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate AT chenmiinfu surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate |
_version_ |
1724537532961521664 |